Tykerb is a medicine containing the active ingredient(s) lapatinib. On this page you will find out more about Tykerb, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: lapatinib
Information for medicine and pack size:
Tykerb 250 mg film-coated tablet, 84
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
TYKERB in combination with an aromatase inhibitor is indicated for the treatment of post-menopausal women with hormone receptor-positive metastatic breast cancer whose tumours overexpress HER2 (ErbB2) and for whom hormonal therapy is indicated. TYKERB, in combination with capecitabine, is indicated for the treatment of patients with advanced/metastatic breast cancer whose tumours overexpress HER2 (ErbB2) and whose tumours have progressed after treatment with an anthracycline, a taxane and trastuzumab. TYKERB, in combination with paclitaxel, is indicated for the first-line treatment of patients with metastatic breast cancer whose tumours overexpress HER2 (ErbB2) and for whom trastuzumab is not appropriate (see Clinical Trials).
Table of characteristics
Biconvex, oval, yellow, film coated tablets with one side plain and the opposite debossed with GS XJG.
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, film coated|
|Route of administration||Oral|
70 tablets: Prescription Only Medicine, or Prescription Animal Remedy
84 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||No information available|
|Life time||2 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 1 results
Tykerb Tablets - myDr.com.au
Tykerb Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 1 results
Oral targeted therapy for cancer | Issue 5 | Volume 38 | Australian Prescriber
Oral targeted therapies are increasingly being used to treat cancer. They work by interfering with specific molecules or pathways involved in tumour...
Read more on Australian Prescriber website